6-K ·Filed May 18, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001575872-26-000341
Notable filing: 6-K
Actionable Insight • Neutral

This filing is a procedural submission of an earnings transcript. As no new data is provided, there is no immediate actionable signal. Monitor the transcript content for any guidance changes or material updates that could affect the stock.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d
RDY ▼ -8.90% at T+60d
NEUTRAL call ✗ call lost -8.90% · α vs SPY -13.75% · entry $13.60 → $12.39
Entry anchored
May 18, 12:59 PM ET
via exchange tick
T+1d
-1.10%
call -1.10% · α -0.45%
$13.45
settled 5mo ago
T+5d
+1.10%
call +1.10% · α -0.52%
$13.75
settled 4mo ago
T+20d
-2.21%
call -2.21% · α -3.79%
$13.30
settled 4mo ago
T+60d
-8.90%
call -8.90% · α -13.75%
$12.39
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's submitted a 6-K filing enclosing the transcript of its Q4 FY2026 earnings call held on May 12, 2026. The filing itself contains no new financial data or material disclosures—it is a routine procedural submission of the call transcript. Traders should review the transcript for any material updates, but this filing alone has no immediate stock impact.

Key Facts

  • Form 6-K filed on May 18, 2026, covering the period ended May 18, 2026.
  • Exhibit 99.1 is a letter to stock exchanges enclosing the earnings call transcript for Q4 FY2026.
  • No financial figures or material business updates are provided in the filing itself.
  • The transcript is available via a weblink included in the exhibit.

Financial Impact

No financial data disclosed in this filing.

Risk Factors

  • The transcript may contain adverse or unexpected commentary not reflected in this filing.
  • Absence of financial details in the filing itself limits visibility into results.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000341
Document: 0001575872-26-000341-index.html0001575872-26-000341
Document: 0001575872-26-000341.txt0001575872-26-000341
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access